ZA95463B - Use of interleukin-12 to prevent graft-versus-host disease - Google Patents

Use of interleukin-12 to prevent graft-versus-host disease

Info

Publication number
ZA95463B
ZA95463B ZA95463A ZA95463A ZA95463B ZA 95463 B ZA95463 B ZA 95463B ZA 95463 A ZA95463 A ZA 95463A ZA 95463 A ZA95463 A ZA 95463A ZA 95463 B ZA95463 B ZA 95463B
Authority
ZA
South Africa
Prior art keywords
interleukin
versus
host disease
prevent graft
prevent
Prior art date
Application number
ZA95463A
Other languages
English (en)
Inventor
Megan Sykes
Stanley F Wolf
Original Assignee
Genetics Inst
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Gen Hospital Corp filed Critical Genetics Inst
Publication of ZA95463B publication Critical patent/ZA95463B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA95463A 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft-versus-host disease ZA95463B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,529 US5573764A (en) 1994-01-21 1994-01-21 Use of interleukin-12 to prevent graft versus host disease

Publications (1)

Publication Number Publication Date
ZA95463B true ZA95463B (en) 1995-09-27

Family

ID=22685309

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95463A ZA95463B (en) 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft-versus-host disease

Country Status (14)

Country Link
US (2) US5573764A (fr)
EP (1) EP0739212B1 (fr)
JP (1) JP3825043B2 (fr)
AT (1) ATE215380T1 (fr)
AU (1) AU698410B2 (fr)
CA (1) CA2181568C (fr)
DE (1) DE69526206T2 (fr)
DK (1) DK0739212T3 (fr)
ES (1) ES2179096T3 (fr)
IL (1) IL112373A (fr)
PT (1) PT739212E (fr)
TW (1) TW349021B (fr)
WO (1) WO1995019786A1 (fr)
ZA (1) ZA95463B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
WO1997016203A1 (fr) * 1995-11-01 1997-05-09 Genetics Institute, Inc. Procedes d'administration d'il-12
WO1998017689A2 (fr) * 1996-10-18 1998-04-30 Valentis Inc. Expression du gene il-12, systemes d'apport et utilisations
EP0931156A2 (fr) * 1996-10-18 1999-07-28 Valentis Inc. Expression de genes, systemes d'apport et utilisations
WO1998034635A1 (fr) * 1997-02-07 1998-08-13 The Wistar Institute Procedes et compositions pour inhiber la production d'interleukine 12
WO1998051327A1 (fr) * 1997-05-16 1998-11-19 Toray Industries, Inc. Agent therapeutique, procede de traitement, agent prophylactique et procede prophylactique destines au traitement de maladies immunologiques chez les chiens et les chats
EP1516630A3 (fr) * 1997-10-31 2006-05-03 Wyeth Utilisation d'anticorps anti-il12 pour empêcher le rejet des greffes
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
WO2003038062A2 (fr) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation et utilisation de cellules tc1 et tc2
WO2003004625A1 (fr) * 2001-07-02 2003-01-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Methodes de generation de cellules humaines th2 cd4+ et utilisations associees
AU2002336417A1 (en) * 2001-08-31 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Methods of generating human cd4+ th1 cells
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
JP2010539993A (ja) * 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
US20100272863A1 (en) * 2009-04-24 2010-10-28 Griebel Jonathan M Soft shaped tortillas
EP2571516B1 (fr) 2010-05-18 2017-11-15 Neumedicines, Inc Formulations d'il-12 pour la stimulation de l'hématopoïèse
WO2012174056A1 (fr) 2011-06-13 2012-12-20 Neumedicines, Inc. Mitigation d'une lésion cutanée par il-12
EP2736530B1 (fr) 2011-07-27 2018-06-06 Neumedicines, Inc Utilisation d'il-12 pour générer de l'érythropoïétine endogène
PL3351261T3 (pl) * 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
US9636381B2 (en) 2012-01-18 2017-05-02 Neumedicines, Inc. Methods for radiation protection by administering IL-12
WO2013158959A1 (fr) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions et procédés pour le traitement de la maladie du greffon contre l'hôte
JP7851612B2 (ja) * 2020-04-17 2026-04-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ｉｌ－１２及びｉｌ－２３ポリペプチドとその使用
JP2023548746A (ja) * 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
JP2025503454A (ja) * 2021-12-17 2025-02-04 ウィリアム マーシュ ライス ユニバーシティ Ｉｌ－１２を発現するカプセル化細胞及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249754A (en) * 1992-03-04 1997-06-24 Schering Corp Interleukin-10 and its use in inhibiting graft vs host disease or tissue rejection
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
US5573764A (en) 1996-11-12
US5756085A (en) 1998-05-26
DE69526206D1 (de) 2002-05-08
EP0739212B1 (fr) 2002-04-03
JP3825043B2 (ja) 2006-09-20
DE69526206T2 (de) 2002-11-21
DK0739212T3 (da) 2002-06-03
PT739212E (pt) 2002-08-30
JPH09508371A (ja) 1997-08-26
EP0739212A1 (fr) 1996-10-30
AU698410B2 (en) 1998-10-29
WO1995019786A1 (fr) 1995-07-27
IL112373A (en) 2006-08-01
ES2179096T3 (es) 2003-01-16
CA2181568C (fr) 2007-09-18
ATE215380T1 (de) 2002-04-15
TW349021B (en) 1999-01-01
IL112373A0 (en) 1995-03-30
AU1687595A (en) 1995-08-08
CA2181568A1 (fr) 1995-07-27

Similar Documents

Publication Publication Date Title
IL112373A0 (en) Use of interleukin-12 to prevent graft versus host disease
SG49658A1 (en) Treatment of condition and disease
EP0441119A3 (en) The use of l-arginine in the treatment of hypertension and other vascular disorders
UA32429C2 (uk) Засіб для лікування нетримання сечі
GB9320747D0 (en) A compress for use in the cold and/or hot treatment of an injury
PL326653A1 (en) Application of epinastin in pain relieving treatments
AU1577792A (en) Implantation tissue and treatment and use methods
ZA931174B (en) Treatment of disease employing hyaluronic acid and nsaids.
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
IL102106A0 (en) Arylethers,their manufacture and methods of treatment
PL324750A1 (en) Expressive construct p16 and posiibility of using it in treating carcinomas
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
ZA935575B (en) Therapeutic agent and its use.
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA929390B (en) The use of D-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects.
NO913054L (no) Vaginal behandlingsprosess og innretning med dusj.
EP0745597A3 (fr) Indanylpipérazines ou homopipérazines mélatonergiques
GB9616549D0 (en) Therapeutic product and its use
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
张钦 et al. EJACULATIO DEFICIENS TREATED WITH ACUPUNCTURE REPORT OF 110 CASES
EP0596937A4 (fr) Plasmalopsychosines et plasmalocerebrosides et procedes de traitement de maladies neuronales les utilisant.
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
GB9005605D0 (en) Treatment of sleep apnoea
ZA963998B (en) 3,4-Disubstituted-phenylsulphonamides and their therapeutic use